Kamada Pharmaceuticals is a company that develops plasma-derived protein therapeutics for orphan indications. It uses its proprietary platform technology for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a liquid form as well as other plasma-derived Immune globulins. The company offers a line of pharmaceutical products intended for administration by injection or infusion.